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Enhanced cell killing and apoptosis of oral squamous cell carcinoma cells 1 
with ultrasound in combination with cetuximab coated albumin 2 
microbubbles 3 
 4 
Abstract 5 
 6 
Targeted microbubbles has the potential to be used for ultrasound (US) therapy and 7 
diagnosis of various cancers. In the present study, US was irradiated to oral squamous cell 8 
carcinoma cells (HSC-2) in the presence of cetuximab coated albumin microbubbles 9 
(CCAM). Cell killing rate with ultrasound treatment at 0.9W/cm
2
 and 1.0W/cm
2
 in the 10 
presence of CCAM was greater compared to non-targeted albumin microbubbles (p<0.05). 11 
On the other hand, selective cell killing was not observed in human myelomonocytic 12 
lymphoma cell line (U937) that had no affinity to cetuximab. Furthermore, US irradiation in 13 
the presence of CCAM showed a five-fold increase of cell apoptotic rate for HSC-2 cells 14 
(21.0±3.8%) as compared to U937 cells (4.0±0.8%). Time-signal intensity curve in a tissue 15 
phantom demonstrated clear visualization of CCAM with conventional US imaging device. 16 
Our experiment verifies the hypothesis that CCAM was selective to HSC-2 cells and may be 17 
applied as a novel therapeutic/diagnostic microbubble for oral squamous cell carcinoma. 18 
 19 
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Introduction 1 
 2 
Head and neck cancer is the sixth most common cancer worldwide [1]. They include 3 
cancers of the larynx, throat, lips, and salivary glands. Oral squamous cell carcinoma (OSCC), 4 
originating in the mouth and lips makes approximately 90% of all oropharyngeal 5 
malignancies [2]. Although smoking and excessive alcohol consumption are prominent oral 6 
cancer risk factors, human papillomavirus infection and population aging have greatly 7 
contributed to the increased cancer incidents in recent years [3]. Efforts have been made on 8 
various aspects for OSCC, including detection techniques, radical removal of the malignant 9 
tissue, and mechanisms involved in cancer initiation and progression. In addition, several 10 
strategies have been proposed to induce tumour sensitivity to radiation or anticancer drugs [4]. 11 
In spite of these recent advances, OSCC still is among the tumour types with a poor 12 
prognosis [5]. Thus, more effective diagnostic and therapeutic strategies are urgently needed 13 
to combat this deadly disease. 14 
Recently, a novel ultrasound/microbubble-mediated technique has been explored as a 15 
potential drug carrier for effective accumulation within various tumour tissues [6-10]. 16 
Furthermore, combining tumour targeting, imaging and therapeutic function into a single 17 
microbubble (MB) has generated great attention because of its ability to simultaneously 18 
diagnosis and treat cancers, to be specific; by means of contrast echography and therapeutic 19 
ultrasound. Microbubble shells made of albumin are especially attractive for its multiple 20 
beneficial features such as, non-antigenicity, biodegradability, easy preparation, 21 
reproducibility, and non-toxicity. Microbubble agents have previously been developed for 22 
ultrasound contrast imaging which contains an air core and stabilized by albumin (Albunex®). 23 
Currently available bubble contrast agent, Optison® (GE Healthcare Systems, PA, USA) has 24 
a perfluoropropane gas core with an albumin shell. Additionally, albumin MBs have a 25 
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potential of becoming a versatile platform for many types of molecular targeted therapy 1 
agents bounded by ionic interaction, or dispersement in the albumin particle matrix [11, 12]. 2 
Various biomolecules such as antibodies can be conjugated onto the surface of albumin MBs 3 
to offer active targeted diagnosis or treatment of cancers. These biomolecules can be 4 
designed to interfere with a specific molecular target or signaling pathway that may play a 5 
key role in tumour growth or progression and induce apoptosis. Cetuximab (Erbitux®) is a 6 
chimeric human/murine monoclonal antibody in the immunoglobulin (Ig) G1 class that 7 
specifically targets the human epidermal growth factor receptor (EGFR) with higher affinity 8 
than the natural ligands, transforming growth factor-α and epidermal growth factor [13, 14]. 9 
Preclinical studies have demonstrated anti-tumour activity of cetuximab such as G0/G1 10 
cell-cycle arrest, induction of apoptosis, inhibition of DNA repair, inhibition of angiogenesis, 11 
inhibition of tumour cell motility, and metastasis [15]. It is currently indicated for the 12 
treatment of locally advanced squamous cell carcinoma of the head and neck in combination 13 
with radiation therapy and for treatment of recurrent or metastatic carcinoma [16]. 14 
The mechanism of cell damage to cancer cells by ultrasound is not clear. However, some 15 
researchers have hypothesized that oscillating MBs during ultrasound exposure attribute to 16 
cell killing [17, 18]. Ultrasound induces cavitation or oscillation of MBs thus generating 17 
violent fluid flow surrounding the bubble. This phenomenon causes shear stress on the cell 18 
membrane leading to cell damage [19]. If this hypothesis proves to be true, it is safe to say 19 
that the less the distance from cavitation occurrence and cell membrane would induce greater 20 
mechanical force to damage or kill cancer cells. Feril et al. [20] have demonstrated enhanced 21 
ultrasound induced apoptosis in the presence of ultrasound contrast agent MBs. It was 22 
suggested that MBs have the potential to be adjuncts in cancer therapy. Custom made MB 23 
that has the function to specially adhere to specific cancer cells such as OSCC could lead to 24 
an ideal theragnostic agent. 25 
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In order to obtain the above objective in the most effective means, we coated an ultrasound 1 
contrast agent albumin MB with cetuximab which can be used for specific targeting of the 2 
EGFR expressed on the surfaces of OSCC. In the present report, the immediate increase in 3 
the selective tumour cell killing and apoptosis by therapeutic ultrasound was compared 4 
between EGFR expressed and non-EGFR expressed tumour cells in vitro. We also evaluated 5 
if this contrast agent can be visualized with a conventional US imaging device. 6 
 7 
Methods & Materials 8 
Preparation of microbubbles 9 
The MBs used in this study had an albumin outer shell, each entrapping perfluoropropane 10 
gas. They were prepared by the following method at our laboratory, according to the 11 
established favorable production conditions. In brief, a 700 μl sterile solution of 0.25 % 12 
human serum albumin (fraction V, purity 96%; Aventis Behring L.L.C., IL, USA) in 13 
phosphate-buffered saline (PBS; 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM 14 
KH2 PO4, pH 7.4; Cosmo Bio Co., Tokyo, Japan) was added in a air filled 2 ml plastic tube. 15 
After air tight sealing, the air within the container was replaced with perfluoro-propane 16 
(C3F8; Takachiho Chemical Industrial Co, Tokyo, Japan) gas using a 23-gauge needle 17 
inserted through a customized 3D printer manufactured cap. The container tubes were then 18 
placed into a high speed shaking tissue homogenizer device (Precellys Evolution, Bertin 19 
Instruments, France), they were shaken at high speeds under the following conditions: 6500 20 
rpm, 6 x 10s duration, 20 second pause between each shaking phase. The MBs were 21 
preserved in a 4 °C condition until use. 22 
 23 
Characterization of microbubble 24 
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In order to measure the physical properties of albumin MBs, a light scattering 1 
measurement system ELSZ - 2000ZS (Otsuka Electronics Co., Osaka, Japan) was used. The 2 
measurement principle is dynamic light scattering (DLS) which observes temporal change or 3 
fluctuation of scattered light from Brownian moving particles which estimates the overall 4 
size distribution of bubbles. The measurement range of the device was 0.6 nm to 10 um. All 5 
measurements were carried out at room temperature by adding 1 mL of the sample to the 6 
glass cell. Repeated measurements were carried out 3 times for each sample, and averaged to 7 
determine particle diameter. The size distribution of the albumin MB is depicted by the curve 8 
shown in Fig. 1. The mean size of albumin MBs used throughout the experiments was 1278 ± 9 
54.49 nm and MB concentration approximately 5 × 108 /mL. 10 
 11 
Cell culture 12 
Oral squamous carcinoma cell line HSC-2 were purchased from JCRB (Japanese 13 
Collection of Research Bioresources) cell bank and cultured in Minimum Essential Medium 14 
(MEM; Nacalai tesque, Kyoto, Osaka, Japan) with 10% Fetal Bovine Serum (Invitrogen Co., 15 
Tokyo, Japan) and was maintained at 37.0℃ in humidified air with 5% CO2. HSC-2 cells 16 
collected by trypsin–EDTA (Gibco, NY, USA) were washed and maintained in fresh medium 17 
immediately before each sonication experiment. Similarly, human myelomonocytic 18 
lymphoma cell line U937 (Japanese Collection of Research Bioresources JCRB Cell Bank) 19 
was cultured in Roswell Park Memorial Institute medium RPMI 1640 (RPMI 1640; Nacalai 20 
tesque, Kyoto, Japan) supplemented with 10% Fetal Bovine Serum (Sigma-Aldrich, MO, 21 
USA) , maintained at 37.0 °C in humidified air with 5% CO2. On the day of experiment, cells 22 
were collected and centrifuged at 100g for 5 min. Both cell lines were free of viral pathogens 23 
with initial viability of more than 99% were used for the actual experiments.  24 
 25 
  6 
Preparation of antibody 1 
Cetuximab is a human-mouse chimeric monoclonal antibody belonging to the IgG1 family. 2 
This treatment is approved by the FDA for metastatic colorectal cancer that express EGFR, 3 
such as head and neck cancer. Cetuximab was purchased from Merck-Serano (Erbitux®, 4 
Geneva, Switzerland) and was mixed in the MB included reagent at concentrations of 125, 5 
250, 375 µg/mL immediately prior to ultrasonic irradiation to the cells. The antibody and 6 
microbubble was bond by electrostatic interactions.  7 
 8 
Cell viability measurement 9 
The number of viable HSC-2 cells and U937 were measured immediately after all 10 
treatments using a trypan blue dye exclusion method. The cell suspensions were mixed with 11 
an equal volume of trypan blue stain (0.4%). We considered that both dead and dying cells 12 
stained with trypan blue as nonviable, and that the cells not stained with trypan blue as viable. 13 
The number of viable cells was counted with a fully automated cell counter (Automated cell 14 
counter TC20, BioRad, CA, USA) that uses multi-focal plane imaging analysis for live/dead 15 
cells. The survival rate of treated cells was calculated as the ratio of the number of surviving 16 
cells to the number of control non-treated surviving cells. Each irradiation and drug condition 17 
treated cell survival rate data consisted of at least four repeated samples (n = 4).  18 
 19 
Ultrasound apparatus and irradiation protocol 20 
Both cancer cells lines HSC-2 or U937 were sonicated in culture multi-wells. The 21 
ultrasound condition and microbubble concentration was based on experiments previous 22 
described [21]. The ultrasound exposure system (Fig 2) consists of 4 independent ultrasound 23 
generators (KTAC-4000, NepaGene, Chiba, Japan) and 4 unfocused-single-20mm diameter 24 
ultrasound transducers (KP-S20, NepaGene, Chiba, Japan). The 24 well cell culture plate 25 
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(SARSTEDT Lumox® multiwell 24, Nümbrecht, Germany) was placed on the acoustic 1 
radiation surface of ultrasound transducers via ultrasound transmission gel (Aquasonic 100, 2 
Parker lab, NJ, USA). The plate bottom consists of a 50 µm thick polystyrene acoustically 3 
transparent film described elsewhere [22] for sufficient ultrasound exposure. The 4 4 
ultrasound transducers were driven by the 4 different ultrasound generators at the driving 5 
frequency of 1.0 MHz, the burst rate of 10 Hz and the duty ratio of 50%, and the ultrasound 6 
were generated simultaneously from the ultrasound transducers. The US generator can 7 
operate at fixed frequency in the continuous wave mode or in the pulsed wave mode. 8 
Ultrasound energy with 3 acoustic intensities Ispta (spatial peak temporal average) of 0.8, 0.9 9 
and 1.0 W/cm2 (150 kPa, 160 kPa, 170 kPa , respectively) were exposed simultaneously to 10 
the 4 wells of the 24 well cell culture plate for 15 second. The 4 wells were sonicated in the 11 
same acoustic conditions by placing each of the multiple plates so that the wells of interest 12 
were perfectly centered above the 4 transducers. Thermal change near the transducer were 13 
monitored by a digital meter connected to one of the four transducers which showed reading 14 
below 25 °C at all times. 15 
HSC-2 cells were re-suspended in fresh MEM medium with 10% FBS at a final 16 
concentration of 1×106 cells/mL. 2 mL of cell suspension were added to the each well of 24 17 
well cell culture plate. 250 µL of cetuximab molecular targeted microbubble was added to the 18 
2 mL of cell suspension in each well. After 5 minutes, ultrasound was exposed to the HSC-2 19 
cells and MBs. US irradiation experiment consisted of four groups: non-treated control, 20 
ultrasound alone, non-targeted albumin MB combined with ultrasound, cetuximab molecular 21 
targeted MB combined with ultrasound. After ultrasound irradiation treatment, HSC-2 cells 22 
were collected immediately from each well of the 24 well plates. Trypan blue dye exclusion 23 
test was performed immediately for measurement of cell survival rate. The cancer cell line 24 
U937 was similarly prepared and treated in the same ultrasound conditions and groups as the 25 
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HSC-2 cells. The ratio of the total number of microbubbles within the medium and cells was 1 
approximately 63 to 1. 2 
 3 
Apoptosis measurement 4 
The apoptotic events of HSC-2 and U937 cancer cells were measure by the Tali® 5 
Image-Based Cytometer (Life Technologies Japan, Tokyo, Japan) which is a 3-channel 6 
(bright field, green fluorescence, red fluorescence). The device captures up to 20 microscopic 7 
slide images per sample and automatically analyses the images with digital image based cell 8 
counting and fluorescence detection algorithms. Briefly, after 6-h incubation in humidified 9 
air with 5 % CO2 at 37 °C, the cancer cells were subjected to trypsinization, a 100 μL aliquot 10 
of cells (1 × 106) from each sample was centrifuged at 100g and resuspended in 100 μL 11 
apoptosis buffer (50 mM HEPES, 700 mM NaCl, 12.5 mM CaCl2, pH 7.4) added to 5 μL 12 
Annexin V (5%; conjugated with Alexa Fluor® 488, Thermo Fisher Scientific, MA, USA) 13 
and incubated at room temperature in the dark for 20 min. Then, the samples were 14 
centrifuged (100g) and resuspended again in 100 μL of the same buffer and added with 1 μL 15 
Propidium Iodide (1% PI; Tali® Viability Kit; Life Technologies Japan, Tokyo, Japan) at 16 
room temperature in the dark for 1–5 min and analysed by Tali® Image-Based Cytometer. 17 
Apoptotic cells showed green fluorescence, late apoptotic cells showed red and green 18 
fluorescence, and live cells showed low or no fluorescence. Apoptosis was calculated as the 19 
percentage of apoptotic cells/the number of total cells in each group. Each measurement was 20 
repeated three times independently. 21 
 22 
Fluorescence microscopy 23 
In order to visualize the existence of cetuximab on the surface of targeted MBs, 24 
fluorescently labelled antibody method was used. Readilink® antibody labelling kit 25 
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specifically fluorescence tags cetuximab. Briefly, solution of 1 mg/ml concentration antibody 1 
labelling fluorescence was suspended with the targeted antibody in PBS. Antibody solution 2 
of 50μl was added to 5μL reaction buffer. After mixing sufficiently several times by pipetting, 3 
the antibody solution total amount (55μl) was added to one vial of ReadiLink dye (BioRad 4 
Laboratory, CA, USA). It was incubated for 60 minutes at room temperature. Fluorescent 5 
block buffer (Quench buffer) was added to 5μl to the reaction mixture solution and incubated 6 
at room temperature for 10 minutes. Molecular Probes® Texas Red Albumin was adjusted to 7 
3% of total concentration of albumin for visualizing albumin MBs. Fluorescent labeled 8 
antibodies, albumin and cells were observed with a bright field and multichannel 9 
fluorescence integrated inverted microscope equipped with a digital camera, and a 10 
touch-screen interface (ZOE ™ Fluorescent Cell Imager Bio-Rad Laboratories, CA, USA). 11 
Green LED channel was: excitation, 480/17 nm; emission: 517/23 nm and red LED channel 12 
was: excitation, 556/20 nm; emission, 615/61 nm. Magnification was 20 times for all 13 
observations. 14 
 15 
Bright field cell/bubble analysis 16 
Five investigators with medical background were randomly selected from our department 17 
and were asked to count the number of MBs in contact with cell surface in each of the 18 
microscopic bright field cell photos provided. Cell images were randomly deprived from 19 
microscopic images obtained in the course of the experiments. A total of 40 condition blinded 20 
photos of HSC-2 cell which half included targeted MBs and the remaining non-targeted MBs. 21 
The microscope magnification rate was 20 times. The counted results were later statistically 22 
analyzed. 23 
 24 
Ultrasound imaging process 25 
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The blood vessel-mimicking flow model system for ultrasound imaging evaluation 1 
consisted of a 3 mm diameter and 15 cm in length lumen in a commercially available tissue 2 
ultrasound phantom (6x15x8cm,VP-3 ATS laboratories, CT, USA). The albumin MB 3 
solution described previously (0.25 % human serum albumin) was diluted 20 times by PBS 4 
and was injected through the vessel at a constant speed of 0.3 ml/min using a syringe 5 
injection pump (YSP-201, YMC Ltd, Kyoto, Japan). Microbubble imaging evaluation was 6 
performed with a conventional clinical ultrasound machine (Logiq 9; GE Healthcare, WI, 7 
USA). A ML6-15 liner array transducer probe with transmission frequency of 6 – 15 MHz 8 
for both standard and contrast-enhanced was used. The ultrasound probe was placed and 9 
fixed on the top surface of flow phantom with ultrasound gel (AQUASONIC® 100, Parker 10 
labs, NJ, USA) between the probe and phantom. Enhanced signal intensity as a function of 11 
time in the lumen of the flow vessel was obtained in the contrast enhance mode.  12 
 13 
Statistics 14 
Measurement data were displayed as mean ± standard deviation (SD). Data was analyzed 15 
using unpaired t-test including Welch’s correction. The statistical significant differences 16 
between various groups were analyzed using SPSS software (IBM, NY, USA). The 17 
probability value of p<0.05 was considered statistically significant. 18 
19 
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Results 1 
 2 
Drug toxicity evaluation 3 
To investigate the immediate cell toxicity of cetuximab alone to HSC-2 and U937 cell 4 
lines, cetuximab was administered at various concentrations and assessed by trypan blue 5 
staining cell viability assay. Cell survival rate of HSC-2 cells at cetuximab concentrations 6 
125µg/ml, 250µg/ml, 375µg/ml were 99.6±4.9%, 98.0±4.3% and 95.4±1.8%, respectively 7 
(Fig. 3A). Similarly, cell survival rate of U937 cells with cetuximab concentrations 125µg/ml, 8 
250µg/ml, 375µg/ml were 99.6±3.7%, 94.6±8.4% and 93.1±4.9%, respectively (Fig. 3B). 9 
Immediate toxicity of cetuximab at these specific concentrations was not observed in both 10 
HSC-2 and U937 cell lines.  11 
 12 
Effect of ultrasound alone 13 
The effect of ultrasound alone at various irradiation intensities to HSC-2 cells and U937 14 
cells are shown in Fig. 4. Cell survival rate of HSC-2 cells after ultrasound treatment at 15 
0.8W/cm2, 0.9W/cm2, 1.0 W/cm2 were 96.5±5.4%, 89.5±9.2% and 76.1±11.7%, 16 
respectively. There were no statistically significant differences (p<0.05) compared to the 17 
control group, but the cell survival rate tended to decrease with increased ultrasound 18 
irradiation intensities. Similar tendency was observed for U937 cells. Cell survival rate 19 
immediately after treatment by ultrasound alone at 0.8W/cm2, 0.9W/cm2, 1.0W/cm2 were 20 
90.1±4.5%, 78.1±2.8% and 79.8±4.6%, respectively. 21 
 22 
Cell killing by targeted microbubbles 23 
Enhanced cell-killing effect of ultrasound in the presence of MBs both in HSC-2 and U937 24 
cells are shown in Fig.4. In order to investigate whether ultrasound in the presence of MBs 25 
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could specifically kill HSC-2 cells, we compared the cell killing effect of 1 
targeted/non-targeted MBs versus ultrasound alone (without MBs) to HSC-2 cells under 2 
various ultrasound intensities (Fig. 4A). There was significant difference of cell survival 3 
between targeted MBs versus ultrasound alone treated cells at 0.9W/cm2 and 1.0W/cm2. No 4 
significant difference of cell killing was observed between targeted MBs and ultrasound 5 
alone treated cell at 0.8W/cm2. Cell survival rate with ultrasound treatment at intensities 6 
0.8W/cm2, 0.9W/cm2 and 1.0W/cm2 in the presence of targeted MBs were 87.2±5.2%, 7 
69.0±7.7%, 60.8±6.7%, respectively. In contrast, cells treated with ultrasound in the presence 8 
of non-targeted MBs, showed no significant difference of cell survival compared to 9 
ultrasound alone treated cells at all ultrasound intensities. To determine if the above results 10 
were specific to EGFR positive cells, the same treatment to U937 cancer cells which have no  11 
EGFR receptors to the cell membrane was performed. Results revealed no difference of cell 12 
killing both for targeted and non-targeted MBs at all ultrasound intensities. Cell survival rate 13 
with ultrasound treatment at intensities 0.8W/cm2, 0.9W/cm2 and 1.0W/cm2 in the presence 14 
of non-targeted MBs were 73.7±10.6%, 75.4±3.8% and 67.2±9.3%, respectively. Similarly, 15 
U937 cells treated with ultrasound at all intensities in the presence of targeted MBs also 16 
revealed no significant difference of cell killing as compared with ultrasound alone treatment.  17 
 18 
Induction of apoptosis 19 
Fig 5 shows the apoptosis rate of apoptotic cells (total of the early and late stages) of both 20 
HSC-2 and U937 cells under the presence of MBs and/or ultrasound treatment. Comparison 21 
of the number of apoptotic cells between HSC-2 and U937 cells resulted in no significant 22 
difference in the controls, US alone irradiated, and non-targeted MBs plus US. Whereas, in 23 
the presence of targeted MBs plus US, there was a five-fold increase of apoptotic cells for 24 
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HSC-2 as compared to U937 cells. Apoptosis induced by ultrasound in the presence of 1 
targeted MB was 4.0±0.8% for U937 cells and 21.0±3.8% for HSC-2 cells.  2 
 3 
Microbubble characterization 4 
Images of fluorescent labeled Cetuximab-MBs were captured by multichannel 5 
fluorescence microscopy and shown in Fig. 6. Albumin MBs appeared as small dark spots in 6 
bright field images, some adhering to the surface of cancer cells (Fig. 6A). Texas Red-stained 7 
albumin MBs were observed on the MBs and adhered or located in the vicinity of the HSC-2 8 
cells (Fig. 6 B). Moreover, in comparison to the uniform red color of cell image in red field, 9 
Readilink® green dye labeled anti-EGFR-antibody  (Cetuximab) could also be observed as 10 
a bright green fluorescence near the cell membrane (Fig. 6 C). After merging the images of 11 
red and green fluorescence images, the location of MBs (red) and the anti-EGFR-antibody 12 
zone (green) overlapped (Fig. 6 D), indicated they were same MBs. 13 
The blinded images of the cells were examined by the investigators and the number of 14 
targeted/non-targeted MBs adhering to HSC-2 cells were counted. The average number of 15 
targeted MBs in contact with the cell membrane surface was 70.1 ± 1.2 per image whereas 16 
the number of non-targeted MBs was 24.5± 0.7 per image (Fig. 7). There was statistical 17 
difference between these two groups (p<0.05).  18 
Ultrasound imaging in a flow phantom was carried out in order to examine the echogenicity 19 
of the albumin MBs. Fig. 8A shows ultrasound images before injection of albumin MBs. 20 
Flow vessel could be characterized within normal tissue phantom by standard ultrasound 21 
imaging. No enhancement was observed in the flow vessels in the contrast-imaging mode. 22 
Whereas, immediately after MB injection, MBs were detected as acoustic signals in standard 23 
mode while enhancement was obtained within the flow vessel lumen by contrast imaging 24 
(Fig. 8B). The region of interest (ROI) was created within the flow vessel lumen. Time signal 25 
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intensity curve, in the lumen of the flow vessel, increased from baseline to peak intensity in 1 
approximately 40 seconds. The targeted and non-targeted albumin MBs could be clearly 2 
visualized by ultrasound imaging (Fig. 8C, D). Signal to noise ratio (SNR) baseline intensity 3 
before injection of albumin MBs was -50.1± 0.1 dB -58.6± 0.2 dB (Fig. 8 A) and enhanced 4 
intensity after injection of albumin MBs was -42.5± 2.4 -40.1± 0.5 dB (Fig. 8 B). Similarly, 5 
baseline intensity before injection was -58.3± 0.2 dB and enhanced intensity after injection of 6 
targeted albumin MBs was -42.8± 0.5 dB. The mechanical index (MI) was 0.11 7 
0.12(frequency 5-16 MHz). Contrast to tissue ratio (CTR) was 15.3 dB for albumin MBs and 8 
15.5 dB for targeted albumin MBs. 9 
10 
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Discussion 1 
There has recently been great expectation of using albumin as a drug carrier [23]. Albumin 2 
is the most abundant protein in the plasma and non-toxic with no immunogenicity. Some of 3 
the research work recently reviewed by Liu et al. [24] have referred albumin as an excellent 4 
candidate for many pharmaceuticals. The amino acid residues on albumin can be readily 5 
linked with therapeutic drugs, imaging reporters and targeting molecules through chemical 6 
conjugation. The enhanced permeability and retention (EPR) effect of albumin is also a 7 
unique advantage for carrying anticancer drugs to specific tumour regions. Albumin is a 8 
natural carrier of hydrophobic molecules with favorable, non-covalent binding characteristics 9 
thus various drugs can be incorporated into the particle matrix because of the different drug 10 
binding sites present in the albumin molecule. Albumin has also been used for ultrasound 11 
contrast agents for some time. One of the early commercial ultrasound contrast agent was an 12 
air-filled albumin microspheres prepared from sonicated 5% human serum albumin. The 2nd 13 
generation albumin ultrasound contrast agent, contained perflutren as a gas core [25]. These 14 
MBs have been shown in the clinical situation to be a useful echocardiographic contrast agent 15 
on coronary blood flow, left ventricular function, and systemic hemodynamics. Recently, 16 
phospholipid-stabilized MBs of sulfur hexafluoride gas or perfluorobutane gas have been 17 
introduced for diagnostic imaging of the liver or breast. These contrast agent MBs typically 18 
have a mean diameter ranging from 1 to 10 µm. In the present study, the albumin MB 19 
average diameter was approximately 1 µm that is relatively small compared to previous 20 
albumin based ultrasound contrast agents. Bubbles smaller than 1 µm, frequently termed as 21 
nanobubbles have recently attracted much attention from the fact that they can cross the 22 
vascular wall and reach tumour cells [26]. Although a portion of our bubbles were in the sub 23 
micron size range, our echography evaluations under physiologically relevant flow conditions 24 
suggests that the echogenic signals are sufficient for enhancing small blood vessels and 25 
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differentiating tumours with normal tissues. However, further in vivo animal studies are 1 
required to assess the feasibility of using this specific MB before final application to the 2 
clinical stage. 3 
Recent advance in investigating the molecular basis of cancer have produced a whole new 4 
generation of promising therapies designed to target specific cell receptors that promote 5 
tumour growth and survival. One of the first novel molecular targeted therapies was 6 
inhibiting activation of the epidermal growth factor receptor (EGFR). Ligand binding induces 7 
receptors to dimerise and activate the intracellular kinase domain present on each receptor, 8 
resulting in phosphorylation of tyrosine residues on each member of the receptor pair. The 9 
EGFR signal network then stimulates multiple cellular responses including proliferation, 10 
survival, angiogenesis and metastasis. Cetuximab specifically binds to the EGFR with high 11 
affinity, preventing the ligand from interacting with the receptor, thus blocking growth 12 
factors from accessing the receptor and EGFR simulation signal transduction pathways [27]. 13 
Previous studies have evaluated the possibility of using external nonionizing or acoustic 14 
energy to enhance the anti-cancer efficiency of cetuximab. van Driel et al. [28] recently 15 
reported of a EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy 16 
in a pre-clinical model of head and neck cancer. These targeted nanobody–conjugates 17 
specifically bound to cells over expressing the EGFR and induced phototoxicity. EGFR 18 
targeted nanobodies proved to be very selective and potent agents that specifically 19 
accumulated in tumours in vivo leading to pronounced tumour necrosis. Alternatively, there 20 
have been reports that low-intensity US also enhances the anticancer activity of cetuximab in 21 
a head and neck cancer cells [29]. Induction of apoptosis was detected by FITC-Annexin V 22 
and PI staining assay, 24 hours after cetuximab and/or US treatment. Western blotting 23 
analysis of the expression of EGFR, phospho-EGFR, and the upregulated activation of 24 
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caspase-3 suggested that US induced the inhibition of EGFR-signaling pathway by 1 
cetuximab.  2 
Since the first introduction of applying MBs other than for ultrasound contrast imaging 3 
[30], a considerable number of studies have been carried out, evaluating the therapeutic 4 
aspects of targeted and non-targeted MBs especially in conjunction with various anticancer 5 
drugs. Heath et al. [31] demonstrated increased uptake of fluorescent labeled cetuximab into 6 
4 head and neck carcinoma cell lines in the presence of a non-targeted commercially 7 
available lipid based MB contrast agent, Definity®. In vivo tumours treated with cetuximab 8 
and adjuvant MB/ultrasound exhibited significant decrease in tumour size at termination 9 
compared with cetuximab alone. Non-targeted MB in combination with other anticancer 10 
drugs such as cisplatin, melphalan, doxorubicin have been reported to increase effectivity 11 
against various cancers [32-34]. A human clinical trial was recently conducted using 12 
ultrasound and MBs to enhance gemcitabine treatment of inoperable pancreatic cancer [35]. 13 
A commercially available lipid based ultrasound contrast agent, SonoVue® was injected 14 
intravenously after a 30 minute gemcitabine administration. The patients were treated with a 15 
clinical ultrasound imagining device during bubble administration. According to the survival 16 
plot comparing patients treated with ultrasound, MBs, and gemcitabine vs gemcitabine alone, 17 
the survival curve indicated that the combined treatment group had nearly twice as high 18 
median survival compared to treatment with gemcitabine alone; from a median of 8.9 months 19 
to 17.6 months. To improve the targeting function of MBs to cancer, monoclonal antibodies 20 
have been linked to the MB shell via protein conjugation for molecular ligands specific to 21 
cancer cells. Knowles et al. [36] first investigated MBs with biotinylated shells that were 22 
conjugated to anti-EGFR antibody cetuximab for such purposes as differentiating benign 23 
from malignant lesions. Significantly improved echogenicity was obtained with this targeted 24 
contrast agent for detecting head and neck squamous cell carcinoma in mice. More recently, 25 
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the same EGFR targeted MBs were applied to glioma tumour cells in mice and irradiated 1 
with therapeutic low intensity pulsed ultrasound [37]. Ultrasound glioma tumour imaging 2 
clearly showed accumulation of the targeted MBs as well as significant suppression of 3 
tumour growth at 35 days compared to non-targeted MBs. 4 
The present experimental results were in agreement with previously reported targeted MB 5 
as to effects on cancer cells only that instead of lipid based shells, our MBs uses human 6 
serum albumin. Interestingly, we found that multiple procedures in manufacturing targeted 7 
albumin MBs were not necessary compared to lipid based MBs where centrifugal washing, 8 
purification, biotin-streptavidin conjugation incubation is essential. Secondly, although lipid 9 
based MBs show great possibilities as drug carriers and ultrasound contrast agents, they are 10 
occasionally known to induce hypersensitivity reactions that are believed to be associated 11 
with complement activation. Furthermore, phospholipids are relatively unstable, being 12 
especially susceptible to enzymatic degradation. Liposome based MBs are often expensive 13 
due to costs associated with extraction, synthesis and storage  (38-40). We believe that our 14 
MBs are more advantageous over lipid based MBs from the above reasons but further 15 
evaluation is warranted to prove the safety and durability of albumin MBs.  16 
The exact mechanisms by which ultrasound specifically killed HSC-2 cells and induced 17 
apoptosis in the presence of targeted MBs are still unknown. In the present study, trypan blue 18 
dye method was performed which directly reflects acute cell damage. Microstreaming, 19 
microjets, stable and inertial cavitation, are possible candidates that could cause transient or 20 
permanent damage to the cell membrane. As is well known, these acoustic phenomena are 21 
induced by the oscillations or destructions of MBs activated under acoustic stimulation. We 22 
recently reported observation with a high-speed microscopic video of the interaction 23 
dynamics between suspended cancer cells and MBs during ultrasound irradiation [17]. It was 24 
suggest that the linear oscillation of MB caused microstreaming well below the inertial 25 
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cavitation threshold resulting in the deformation of the cell geometry. The shear stress upon 1 
the cell membrane could only be achieved when cell and bubble is within a short distance. As 2 
sonoporation and gene delivery into cells were demonstrated in this particular study, it is 3 
likely that mechanical stress to the cell membrane and underlining cell structure beneath 4 
could also initiate apoptosis. Conventional US contrast agents are known to activate caspases, 5 
a group of enzymes involved in apoptotic cascade events [41]. Furthermore, previous studies 6 
have suggested that the location and the number of MB can determine the degree of damage 7 
and repairing of cell membrane [42]. The cell-bubble distance would be a critical factor for 8 
defining the shear stress on the cell membrane, hence, our findings of increased cell killing 9 
and apoptosis induction by adhering CCAM to cell membrane surface are consistent with this 10 
hypothesis. Also the fact that relatively high ratio of the number of sub-micron sized albumin 11 
bubbles included in our experiment may have to some extent, altered the efficiency of cell 12 
killing and apoptosis. Nevertheless, as the present study is limited to in vitro situations, 13 
further optimizations of the ultrasound conditions and MB targeting in animal studies are 14 
necessary to achieve clinically relevant therapeutic efficacy. 15 
 16 
Conclusion 17 
In conclusion, we successfully demonstrated that low intensity US irradiation in 18 
conjunction with cetuximab coated albumin MBs selectively killed and induced apoptosis in 19 
EGFR- expressing oral squamous cell carcinoma cells. As this MB was easily visualized with 20 
conventional ultrasound contrast imaging device, similar albumin based targeting MB agent 21 
may become a promising platform for theranostics of various carcinomas. 22 
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Legends 1 
 2 
Fig. 1. Characterization of CCAM by light scattering measurement system. Size distribution 3 
of microbubble diameter (nm). 4 
Fig. 2. Immediate cytotoxicity of cetuximab at various concentrations to (A) HSC-2 cells and 5 
(B) U937 cells. 6 
Fig. 3. Comparison of cell survival rate after US irradiation at various intensities. (A) HSC-2 7 
cells and (B) U937 cells. Each data point represents mean ± S.D. (n=4, *p<0.05, ns=not 8 
significant). 9 
Fig. 4. Change of percentage of apoptotic cells after US irradiation at an intensity of 10 
0.9W/cm2 for 15 sec in the presence of targeted bubble cetuximab (375 µg/mL). Each data 11 
point represents mean ± S.D. (n=4, *p<0.05, ns=not significant)). 12 
Fig. 5. Representative bright field and fluorescent microscopic images of HSC-2 cells in the 13 
presence of microbubbles. Scale bar in all images are 30µm. (A) Bright field image of HSC-2 14 
cells and microbubbles, (B) fluorescent microscopic image of cells (a), Texas red tagged 15 
albumin microbubbles (b), (C) FITC-tagged cetuximab coated microbubbles, (D) merged 16 
image of both fluorescent albumin and cetuximab coated microbubbles. 17 
Fig. 6. Comparison of the number of targeted or non-targeted microbubbles adhering to the 18 
surface of HSC-cells. Each data point represents mean ± S.D. (n=5, *p<0.05) 19 
Fig. 7. Ultrasound images from the flow model phantom study. Ultrasound images before (A) 20 
and after (B) injection of albumin microbubbles into flow vessel (left: standard imaging. 21 
right: contrast enhanced imaging). (C) Albumin microbubble time-signal intensity curve in 22 
the lumen of flow vessel (the region of interest (ROI), yellow circle area). (D) Cetuximab 23 
coated albumin microbubble time-signal intensity curve. 24 
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